Acadia Pharmaceuticals (ACAD) received a negative opinion from the European Medicines Agency for Daybu, an experimental treatment for neurodevelopmental disorder Rett syndrome, the regulator said Friday.
The EMA recommended refusing marketing authorization for Daybu, and the company may request a re-examination of the opinion within 15 days of receiving the opinion, the regulator added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.